New ABPM Classification for Kids; HDL-C Paradox; Gene Therapy for Refractory Angina

Myocarditis was adjudicated as very likely or probable in more than half of COVID long-haulers in a study also reporting evidence of persisting multisystem cardio-renal injury more than a year after infection. (Nature Medicine)

The American Heart Association eliminated blood pressure (BP) load from ambulatory BP monitoring classification in children and adolescents, noting that this metric has not been shown to have additional value over mean BP. (Hypertension)

Too much of a good thing? Very high levels of HDL cholesterol were associated with early death in people with coronary artery disease. (JAMA Cardiology)

Regeneron said a small phase III trial showed that evinacumab (Evkeeza) nearly halved LDL cholesterol in children with homozygous familial hypercholesterolemia taking other lipid-lowering therapies.

The V-LAP implant, placed in the left atrial wall of the heart to remotely calculate left atrial pressure, met endpoints in a first-in-human study counting 30 heart failure patients, Vectorious Medical Technologies announced.

For heart failure with preserved ejection fraction, splanchnic ablation for volume management appears promising. (European Journal of Heart Failure)

Stroke survivors with complicated nonstenosing carotid artery plaques were at high risk of a recurrent stroke. (Journal of the American College of Cardiology)

FDA approved Medtronic’s IN.PACT 018 paclitaxel-coated balloon — the successor to the IN.PACT Admiral drug-coated balloon — for the treatment of peripheral arterial disease in the superficial femoral and popliteal arteries, the manufacturer announced.

Could cardiopulmonary exercise testing have identified responders to percutaneous coronary intervention (PCI) in the ORBITA trial? (European Heart Journal)

Outcomes were similar after PCI for diffuse, long lesions whether operators had opted for one drug-eluting stent or another, a meta-analysis found. (JACC: Asia)

Investigational gene therapy XC001 showed promise as a treatment for refractory angina in an early-stage study, according to XyloCor Therapeutics.

UltraSight’s artificial intelligence technology may enable even medical assistants to perform cardiac ultrasound imaging.

Sending educational brochures in the mail made no difference in oral anticoagulation uptake among atrial fibrillation patients who were candidates for these medications. (JAMA Network Open)

Behold the opossum, the mammal with the longest postnatal window of myocardial regeneration. (Circulation)